NAD+: Clinical Guide for Prescribing Practices
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells that plays critical roles in energy metabolism, DNA repair, and cellular signaling. NAD+ levels decline with age, and supplementation via IV or subcutaneous injection has become a cornerstone of longevity and anti-aging clinical practice.
Also Known As
How NAD+ Works
NAD+ serves as an essential coenzyme for over 500 enzymatic reactions, functioning as an electron carrier in mitochondrial oxidative phosphorylation (complexes I through IV) and as a substrate consumed by sirtuins (SIRT1-7), PARPs (poly-ADP-ribose polymerases), and CD38 [3]. Sirtuin activation by NAD+ promotes histone deacetylation, enhancing DNA repair, mitochondrial biogenesis, and anti-inflammatory gene expression [4]. PARP activity (DNA repair) and CD38 activity (immune cell signaling) both consume NAD+, creating competition for a limited substrate pool that becomes increasingly depleted with aging [3].
Clinical Evidence
Human clinical trials of NAD+ precursors (NMN and NR) have demonstrated significant elevation of blood NAD+ levels [2]. A 2021 randomized controlled trial in Science (MIB-626/NMN) showed dose-dependent NAD+ elevation and improved insulin sensitivity in overweight adults [1]. The 2018 Elysium/ChromaDex NR trial published in Nature Communications confirmed safe, sustained NAD+ elevation in healthy middle-aged and older adults [2]. Direct IV NAD+ bypasses the precursor conversion pathway, providing immediate bioavailability. Long-term outcomes data from NAD+ supplementation trials (cardiovascular events, mortality, cancer incidence) are not yet available.
Clinical Uses
Patient Selection and Screening
Appropriate for patients experiencing age-related fatigue and cognitive decline [4], those with documented mitochondrial dysfunction or chronic fatigue conditions, patients in addiction recovery (particularly alcohol and opioid withdrawal support), and athletes or executives seeking cognitive and physical performance optimization. Screen for active malignancy (NAD+ role in tumor cell metabolism is complex) [3]. Patients with anxiety or insomnia should start with lower doses, as NAD+ can be stimulatory. IV protocols require adequate venous access and patient tolerance for extended infusion times.
Dosing and Administration
IV infusion: 250 to 750 mg over 2 to 4 hours for standard longevity protocols; up to 1000 to 1500 mg over 6 to 8 hours for addiction recovery loading. Start infusion slowly (first 30 minutes at reduced rate) to assess tolerance. Subcutaneous injection: 50 to 200 mg daily for home maintenance between IV sessions. Loading protocols typically include 4 to 6 IV sessions over 2 weeks, followed by monthly or bimonthly IV maintenance with daily subcutaneous injections between visits [2]. Reduce infusion rate immediately if patient develops chest pressure, nausea, or cramping.
Route: Intravenous infusion, subcutaneous injection, intramuscular injection
Protocol notes: Administered via intravenous infusion (250-1000mg over 2-4 hours) or subcutaneous injection (50-100mg). IV protocols often involve loading phases followed by maintenance. Subcutaneous formulations allow home administration.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
NAD+ IV therapy is among the highest-revenue services in longevity medicine, with per-session pricing ranging from $500 to $1500+ depending on dose and market [3]. The combination of IV loading protocols (high-margin, in-clinic) with home subcutaneous maintenance prescriptions creates a dual revenue stream with strong patient retention. Addiction recovery programs utilizing high-dose NAD+ protocols can command premium pricing for intensive multi-day treatment packages. The extended infusion time (2 to 4+ hours) also drives ancillary revenue through bundled services during the visit.
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe NAD+ through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What is the difference between IV and subcutaneous NAD+?
What evidence supports NAD+ supplementation for anti-aging?
How should practices structure NAD+ programs for profitability?
References
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
- Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.
- Rajman L, et al. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547.
- Braidy N, et al. Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related neurodegenerative diseases. Antioxid Redox Signal. 2019;30(2):251-294.
Related Peptides in Metabolic & Longevity
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe NAD+ Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe NAD+ Through Karpa